Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | FDPS | P14324 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.32 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL8469209 | 1.00 | TSHR (0.50) | TSHRALDH1A1FDPSTDP1OPRM1 | |
| Bromide SCHEMBL6760465 | 1.00 | TSHR (0.50) | TSHRALDH1A1FDPSTDP1OPRM1 | |
| Bromide SCHEMBL5552303 | 1.00 | TSHR (0.50) | TSHRALDH1A1FDPSTDP1OPRM1 | |
| Bromide SCHEMBL8466601 | 0.96 | TSHR (0.44) | TSHRALDH1A1FDPSTDP1OPRM1 | |
| Bromide SCHEMBL6549989 | 0.96 | TSHR (0.44) | TSHRALDH1A1FDPSTDP1OPRM1 | |
| Bromide SCHEMBL5551153 | 0.96 | TSHR (0.44) | TSHRALDH1A1FDPSTDP1OPRM1 | |
| Bromide SCHEMBL5550558 | 0.96 | TSHR (0.44) | TSHRALDH1A1FDPSTDP1OPRM1 | |
| Bromide SCHEMBL5550949 | 0.96 | TSHR (0.44) | TSHRALDH1A1FDPSTDP1OPRM1 | |
| Bromide SCHEMBL8467090 | 0.96 | TSHR (0.44) | TSHRALDH1A1FDPSTDP1OPRM1 | |
| SCHEMBL5547751 | 0.94 | TSHR (0.46) | TSHRALDH1A1FDPSTDP1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070190021-A1 | Poly(diallylamine)-based bile acid sequestrants | HOLMES-FARLEY STEPHEN R | 2007-08-16 | — | — | US | disclosed |
| US-7125547-B2 | Poly(diallylamine)-based bile acid sequestrants | GENZYME CORPORATION (US) | 2006-10-24 | — | — | US | disclosed |
| US-20040151687-A1 | Poly(diallylamine)-based bile acid sequestrants | GENZYME CORPORATION | 2004-08-05 | — | — | US | disclosed |
| US-6726905-B1 | LOWERING SERUM PHOSPHATE | GENZYME CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-6610283-B1 | Method for removing bile acids from a patient and certain polymers of use in the method. The method comprises the step of administering to the patient a therapeutically effective amount of a polymer composition which includes a a | GENZYME CORPORATION | 2003-08-26 | — | — | US | disclosed |
| US-6517825-B1 | Polyether backbone and amino or ammonium groups pendant therefrom | GELTEX PHARMACEUTICALS, INC. | 2003-02-11 | — | — | US | disclosed |
| EP-1094801-A2 | POLY(DIALLYLAMINE)-BASED BILE ACID SEQUESTRANTS | GELTEX PHARMACEUTICALS, INC. (US) | 2001-05-02 | — | — | EP | disclosed |
| US-6203785-B1 | ADMINISTERING CROSSLINKED CATIONIC POLYMER ANTICHOLESTEROL AGENTS | GELTEX PHARMACEUTICALS, INC. | 2001-03-20 | — | — | US | disclosed |
| US-6190649-B1 | ORALLY ADMINISTERING TO THERAPEUTICALLY EFFECTIVE AMOUNT OF MODIFIED POLYETHER CONTAINING AMINE SALT OR QUATERNARY AMMONIUM GROUPS | GELTEX PHARMACEUTICALS, INC. | 2001-02-20 | — | — | US | disclosed |
| WO-2000064428-A2 | POLYETHER-BASED BILE ACID SEQUESTRANTS | GELTEX PHARMACEUTICALS, INC. (US) | 2000-11-02 | — | — | WO | disclosed |
| US-5969090-A | QUATERNIZED CROSSLINKED HYDROCARBON AMINE POLYMER | GELTEX PHARMACEUTICALS, INC. (US) | 1999-10-19 | — | — | US | disclosed |
| WO-1999022743-A1 | POLY(DIALLYLAMINE)-BASED PHOSPHATE BINDERS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-05-14 | — | — | WO | disclosed |
| US-5900475-A | MODIFIED POLYALLYLAMINE; ANTICHOLESTEROL AGENT | GELTEX PHARMACEUTICALS, INC. (US) | 1999-05-04 | — | — | US | disclosed |
| WO-1998029107-A2 | POLY(DIALLYLAMINE)-BASED BILE ACID SEQUESTRANTS | GELTEX PHARMACEUTICALS, INC. (US) | 1998-07-09 | — | — | WO | disclosed |
| EP-0830390-A1 | HYDROPHOBIC HETEROATOM-CONTAINING SEQUESTRANT FOR CHOLESTEROL DEPLETION | GELTEX PHARMACEUTICALS, INC. (US) | 1998-03-25 | — | — | EP | disclosed |
| WO-1996039449-A1 | HYDROPHOBIC HETEROATOM-CONTAINING SEQUESTRANT FOR CHOLESTEROL DEPLETION | GELTEX PHARMACEUTICALS, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070190021-A1 | Poly(diallylamine)-based bile acid sequestrants | NR1H4, SLC10A2, SLC10A1 | TSHR 4075/4885ALDH1A1 2873/4885FDPS 2092/4885 |
| US-20040151687-A1 | Poly(diallylamine)-based bile acid sequestrants | NR1H4, SLC10A2, SLC10A1 | TSHR 4388/4885ALDH1A1 2717/4885FDPS 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.